Correlation Between NYSE Composite and Artiva Biotherapeutics,
Can any of the company-specific risk be diversified away by investing in both NYSE Composite and Artiva Biotherapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NYSE Composite and Artiva Biotherapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between NYSE Composite and Artiva Biotherapeutics, Common, you can compare the effects of market volatilities on NYSE Composite and Artiva Biotherapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NYSE Composite with a short position of Artiva Biotherapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of NYSE Composite and Artiva Biotherapeutics,.
Diversification Opportunities for NYSE Composite and Artiva Biotherapeutics,
0.13 | Correlation Coefficient |
Average diversification
The 3 months correlation between NYSE and Artiva is 0.13. Overlapping area represents the amount of risk that can be diversified away by holding NYSE Composite and Artiva Biotherapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Artiva Biotherapeutics, and NYSE Composite is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NYSE Composite are associated (or correlated) with Artiva Biotherapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Artiva Biotherapeutics, has no effect on the direction of NYSE Composite i.e., NYSE Composite and Artiva Biotherapeutics, go up and down completely randomly.
Pair Corralation between NYSE Composite and Artiva Biotherapeutics,
Assuming the 90 days trading horizon NYSE Composite is expected to generate 0.14 times more return on investment than Artiva Biotherapeutics,. However, NYSE Composite is 7.23 times less risky than Artiva Biotherapeutics,. It trades about -0.29 of its potential returns per unit of risk. Artiva Biotherapeutics, Common is currently generating about -0.15 per unit of risk. If you would invest 2,020,982 in NYSE Composite on September 28, 2024 and sell it today you would lose (84,532) from holding NYSE Composite or give up 4.18% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Insignificant |
Accuracy | 100.0% |
Values | Daily Returns |
NYSE Composite vs. Artiva Biotherapeutics, Common
Performance |
Timeline |
NYSE Composite and Artiva Biotherapeutics, Volatility Contrast
Predicted Return Density |
Returns |
NYSE Composite
Pair trading matchups for NYSE Composite
Artiva Biotherapeutics, Common
Pair trading matchups for Artiva Biotherapeutics,
Pair Trading with NYSE Composite and Artiva Biotherapeutics,
The main advantage of trading using opposite NYSE Composite and Artiva Biotherapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NYSE Composite position performs unexpectedly, Artiva Biotherapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Artiva Biotherapeutics, will offset losses from the drop in Artiva Biotherapeutics,'s long position.NYSE Composite vs. Ziff Davis | ||
NYSE Composite vs. Zijin Mining Group | ||
NYSE Composite vs. Cheniere Energy Partners | ||
NYSE Composite vs. Perseus Mining Limited |
Artiva Biotherapeutics, vs. Fate Therapeutics | ||
Artiva Biotherapeutics, vs. Caribou Biosciences | ||
Artiva Biotherapeutics, vs. Karyopharm Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Complementary Tools
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |